

VU Research Portal

Too Costly & Too Scarce

Ewen, M.A.

2016

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Ewen, M. A. (2016). *Too Costly & Too Scarce: Price, availability and affordability of medicines in low- and middle-income countries*.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

References

1. Health Action International. Universal access to medicines for non-communicable diseases: within our grasp but out-of-reach. Briefing note for delegates to the UN NCD High Level meeting, September 2011.
2. World Health Organization. Equitable access to essential medicines: a framework for collective action. Geneva: World Health Organization, 2004.
3. O'Donnell O, van Doorslaer E, Rannan-Eliya RP, Somanathan A, Adhikari SR, Akkazieva B, et al. Who pays for health care in Asia? *J Health Economics* 2008;27(2):460-475.
4. Wagner A, Johnson Graves A, Reiss SK, LeCates R, Zhang F and Ross-Degnan D. Access to care and medicines, burden of health care expenditures, and risk protection: results from the World Health Survey. *Health Policy* 2011;100(2-3):151-158.
5. Searles A, Doran E, France TA, Henry D. The affordability of prescription medicines in Australia: are copayments and safety net thresholds too high? *Australian Health Review* 2012;37(1):32-40
6. Wagner A et al. Sub-analysis of data in the 2002/3 World Health Survey (unpublished)
7. World Health Organization. Options for financing and optimizing medicines in resource-poor countries. The World Medicines Situation 2011. Available at <http://apps.who.int/medicinedocs/en/m/abstract/Js20033en/>
8. McIntyre D, Thiede M, Dahlgren G, Whitehead M. What are the economic consequences for households of illness and of paying for health care in low- and middle-income country contexts? *Soc Sci Med* 2006; 62: 858-65.
9. Hogerzeil HV. Essential medicines and human rights: what can they learn from each other? *Bull World Health Organ* 2006;84(5):371-375.
10. World Health Organization. Access to essential medicines as part of the right to health. The World Medicines Situation 2011. Available at <http://apps.who.int/medicinedocs/en/m/abstract/Js18772en/>
11. World Health Organization. Global health trends: global burden of disease and pharmaceutical needs. The World Medicines Situation 2011. Available at <http://apps.who.int/medicinedocs/en/m/abstract/Js20036en/>
12. Declaration of Alma-Ata. International Conference on Primary Health Care, Alma-Ata, USSR.6-12 September 1978. Available at <http://apps.who.int/medicinedocs/documents/s21369en/s21369en.pdf>
13. World Health Organization. Selection of essential medicines. The World Medicines Situation Report 2011. Available at <http://apps.who.int/medicinedocs/en/m/abstract/Js18770en/>
14. World Health Organization. The rational use of drugs. Report of the conference of experts, Nairobi 25-29 November 1985. Available at <http://apps.who.int/medicinedocs/en/d/Js17054e/>
15. World Health Organization. Guidelines for Developing National Drug Policies. 1988 Available at <http://apps.who.int/medicinedocs/en/d/Js19151en/>
16. World Health Organization, Regional Office for Europe. Drugs and Money (First edition). Copenhagen: World Health Organization, 1983
17. World Health Organization, Regional Office for Europe. Drugs and Money (Seventh edition). Copenhagen: World Health Organization, 2003
18. Management Sciences for Health. International Drug Price Indicator Guide. Available at <http://erc.msh.org/mainpage.cfm?file=1.0.htm&module=DMP&language=English>
19. World Health Organization. World Drug Situation Report. Geneva: World Health Organization, 1988

20. Dag Hammarskjold Foundation. Making national drug policies a development priority: a strategy paper and six country stories. Uppsala: Dag Hammarskjold Foundation, 1995
21. 't Hoen E. Private Patents and Public Health. Amsterdam: Health Action International, 2016. Available at <http://accesstomedicines.org/>
22. Watal J. Pharmaceutical patents, prices and welfare losses: Policy options for India under the WTO TRIPS agreement. *The World Economy* 2000;23(5):733-52.
23. Jacobzone S. Pharmaceutical policies in OECD countries: reconciling social and industrial goals. OECD (Labour Market and Social Policy Occasional Papers, No. 4) Available at http://www.oecd-ilibrary.org/social-issues-migration-health/pharmaceutical-policies-in-oecd-countries_323807375536
24. Prices, availability and affordability of medicines in Pakistan. 2006. Available at <http://haiweb.org/wp-content/uploads/2015/07/Pakistan-Report-Pricing-Surveys.pdf>
25. Patel A, Thawani V and Ghurpure K. Medicine prices, availability and affordability. Report of four regions in Maharashtra, India, 2005. Available at <http://haiweb.org/wp-content/uploads/2015/07/India-Maharashtra-4-Regions-Report-Pricing-Surveys.pdf>
26. Survey of the prices of drugs in Morocco (in French), 2004. Available at <http://haiweb.org/wp-content/uploads/2015/07/Morocco-Report-Pricing-Surveys.pdf>
27. Sallouta R, Ali R, Sijari AB. Prices, availability, affordability and price components in Syria. 2004. Available at <http://haiweb.org/wp-content/uploads/2015/07/Syria-Report-Pricing-Surveys.pdf>
28. Bala K, Lanza O, Kaur SL. Retail drug prices: the law of the jungle. *HAI News* 1998; 100: 2-4,13-16.
29. Sagoo K, Bala K. HIV/AIDS: Improving access to essential drugs. *HAI News*. December 1999/January 2000; 110: 1-3.
30. Myhr K. Comparing prices of essential drugs between four countries in East Africa and with international prices. Nairobi, Médecins Sans Frontières, 2000.
31. Resolution WHA 54.11. WHO Medicines Strategy. In: Fifty-fourth World Health Assembly, Geneva, 14-22 May 2001. Volume 1. Resolutions and decisions, and list of participants. Geneva: World Health Organization, 2001.
32. Resolution WHA 55.14. Ensuring accessibility of essential medicines. In: Fifty-fifth World Health Assembly, Geneva, 13-18 May 2002. Volume 1. Resolutions and decisions, and list of participants Geneva: World Health Organization, 2002.
33. World Health Organization and Health Action International. Medicine prices: a new approach to measurement. Working draft for field-testing and revision. Geneva: World Health Organization and Health Action International, 2003
34. WHO/HAI price database <http://haiweb.org/what-we-do/price-availability-affordability/price-availability-data/> and survey reports <http://haiweb.org/survey-related-reports/>
35. World Health Organization and Health Action International. Measuring medicine prices, availability, affordability, and price components. Geneva: World Health Organization and Health Action International, 2008.
36. Ball D, Mirza Z, Ewen M. Prices, availability and affordability of medicines in the World Health Organization Eastern Mediterranean Region: a synthesis report of medicine price surveys undertaken in selected World Health Organization Eastern Mediterranean Region countries. Cairo: World Health Organization, 2008.
37. Gelders S, Ewen M, Noguchi N and Laing R. Price, availability and affordability. An international comparison of chronic disease medicines. Cairo: World Health Organization and Health Action International, 2006.
38. Baber ZUD, Ibrahim MIM, Singh H, Bukahri NI, Creese, A. Evaluating drug prices, availability, affordability, and price components: Implications for access to drugs in Malaysia. *PLoS Med* 4(3): e82. doi:10.1371/journal.pmed.0040082

39. Kotwani A, Ewen M, Dey D, Iyer S, Lakshmi PK, Pate, A, Raman K, Singhal GL, Thawani V, Tripathi S, Laing R. Prices and availability of common medicines at six sites in India using a standard methodology. *Indian J Med Res* 2007; 125: 645–54.
40. Chahal HS, St Fort, N. and Bero, L. Availability, prices and affordability of essential medicines in Haiti. *J Glob Health* 2013 Dec; 3(2): 020405. Doi:10.7189/jogh.03.02405.
41. Yang H, Dib HH, Zhu M, Qi G, Zhang X. Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China. *Health Policy Plan* 2010; 25: 219-229.
42. Ganga Senarathna SMDL, Mannapperuma , Rohini Fernandopulle BM. Medicine prices, availability and affordability in Sri Lanka. *Indian J Pharmacol* 2011 Feb; 43(1): 60-63.
43. Jiang M, Yang S, Yan K, Liu J, Zhao J, Fang Y. Measuring access to medicines: a survey of prices, availability and affordability in Shaanxi Province of China. *PLoS ONE* 8(8): e70836. doi:10.1371/journal.pone.0070836.
44. Jiang M, Zhou Z, Wu L, Shen Q, Lv B, Wang X, Yang S, Fang Y. Medicine prices, availability, and affordability in the Shaanxi Province in China: implications for the future. *Int J Clin Pharm* 2015 Feb; 37(1): 12-17. doi:10.1007/s11096-014-0037-4.
45. Sharma A, Rorden L, Ewen M, Laing R. Evaluating availability and price of essential medicines in Boston area (Massachusetts, USA) using the WHO/HAI methodology. *J Pharm Policy Pract* 2016 Apr 5; 9;12. doi:10.1186/s40545-016-0059-5.
46. Bertoldi AD, Helfer AP, Camargo AL, Tavares NU, Kanavos P. Is the Brazilian pharmaceutical policy ensuring population access to essential medicines? *Global Health* 2012; 8: 6. doi: 10.1186/1744-8603-8-6.
47. Nguyen AT, Knight R, Mant A, Minh Cao Q, Auton, M. Medicine prices, availability and affordability in Vietnam. *Southern Med Review* 2009;2:2-9.
48. Sooksriwong C, Yoongthong W, Suwattanapreeda S, Chanjaruporn F. Medicine prices in Thailand: a result of no medicine pricing policy. *Southern Med Review* 2009 2; 2: 10-14.
49. Xiaoyu X, Weixia L, Jun L, Xuan Z, Cog F, Xu W, Shuzhan C. A survey of the availability, prices and affordability of medicines in Jiangsu Province, China. *BMC Health Services Research* 2015; 15: 345. doi:10.1186/s12913-015-1008-8
50. Espin J, Rovera J. Review Series of Pharmaceutical Pricing Policies and Interventions: Working Paper 1: External reference pricing. World Health Organization and Health Action International, 2011. Available at <http://haiweb.org/what-we-do/price-availability-affordability/resources-for-pricing-policies/>
51. Faden L, Vialle-Valentin C, Ross-Degnan D, Wagner A. Review Series on Pharmaceutical Pricing Policies and Interventions: Working Paper 2: The Role of Health Insurance in the Cost-Effective Use of Medicines. World Health Organization and Health Action International, 2011. Available at <http://haiweb.org/what-we-do/price-availability-affordability/resources-for-pricing-policies/>
52. Ball D. Review Series on Pharmaceutical Pricing Policies and Interventions: Working Paper 3: The Regulation of Mark-ups in the Pharmaceutical Supply Chain. World Health Organization and Health Action International, 2011. Available at <http://haiweb.org/what-we-do/price-availability-affordability/resources-for-pricing-policies/>
53. Hawkins L. Review Series on Pharmaceutical Pricing Policies and Interventions: Working Paper 4: Competition Policy. World Health Organization and Health Action International, 2011. Available at <http://haiweb.org/what-we-do/price-availability-affordability/resources-for-pricing-policies/>
54. Creese A. Review Series on Pharmaceutical Pricing Policies and Interventions: Working Paper 5: Sales Taxes on Medicines. World Health Organization and Health Action International, 2011. Available at <http://haiweb.org/what-we-do/price-availability-affordability/resources-for-pricing-policies/>

55. Whyte P, Hall C. Review Series of Pharmaceutical Pricing Policies and Interventions: Working Paper 6: The role of health technology assessment in medicine pricing and reimbursement. World Health Organization and Health Action International, 2014. Available at <http://haiweb.org/what-we-do/price-availability-affordability/resources-for-pricing-policies/>
56. United Nations General Assembly. Political declaration of the High-level Meeting of the General Assembly on the prevention and control of non-communicable diseases. New York: United Nations General Assembly, 2012. Document No. 66/2
57. World Health Organization. Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020. Geneva: World Health Organization, 2013.
58. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Jonchere K and Hill S. Prices, costs and affordability of new medicines for Hepatitis C in 30 countries: an economic analysis. *PLoS Med* 2016; 13(5): e1002032. doi: 10.1371/journal.pmed.1002032.s003.
59. 't Hoen E. Access to cancer treatment: a study of medicine pricing issues with recommendations for improving access to cancer medication. Oxfam GB, 2015. Available at <http://policy-practice.oxfam.org.uk/publications/access-to-cancer-treatment-a-study-of-medicine-pricing-issues-with-recommendati-344070>.
60. Centre for Pharmaceutical Management. Defining and measuring access to essential drugs, vaccines and health commodities: report of the WHO-MSH consultative meeting.2003. Ferney-Voltaire, France, December 11-13, 2000.
61. World Health Organization. Equitable access to essential medicines: a framework for collective action. *Policy Perspectives on Medicines* 2004c; 8: 1-6.
62. Frost IJ, Reich MR. How do good health technologies get to poor people in poor countries. Boston MA: Harvard Centre for Population and Development Studies, 2010.
63. Bigdeli M, Bart J, Tomson G, Laing R, Ghaffar A, Dujardin B, Van Damme W. Access to medicines from a health system perspective. *Health Policy Plan* 2013; 28: 692-704.
64. Beran D, Yudkin JS. Diabetes care in sub-Saharan Africa. *Lancet* 2006; 368: 1689-1695.
65. Information about the ACCISS Study is available at <http://haiweb.org/what-we-do/acciss/>
66. UNRWA. The annual report of the Department of Health. Amman: UNRWA, 2010. Available at <http://www.unrwa.org/userfiles/2011052062220.pdf>
67. Kaplan WA, Ritz LS, Vitello M. Local production of medical technologies and its effect on access in low and middle income countries: a systematic review of the literature. *South Med Rev*. 2011 Dec; 4(2): 51-61. doi: 10.5655/smr.v4i2.1002.
68. Sweileh W, Jaradat N, Mustafa A. Antibiotic drug cost variations in Palestine: physicians and patients dilemma. *An-Najah Univ. J. Res.* 2004;18(1):73-79.
69. Kuanpoth J. Patents and access to antiretroviral medicines in Vietnam after World Trade Organization accession. *J World Intell Prop* 2007;10:201-224.
70. Chowdury N, Kabir ER. Per pill price differences across therapeutic categories: a study of the essential drug brands marketed by multinational and local pharmaceutical companies in Bangladesh. *African J Marketing Mgt* 2009;1:220-226.
71. Shafie AA, Hassali MA. Price comparison between innovator and generic medicines sold by community pharmacies in the state of Penang, Malaysia. *J Generic Med* 2008;6:35-42.
72. World Health Organization. Medicines Strategy 2008-2013. Geneva: World Health Organization, 2008.
73. Madden JM, Edson M, Ewen M, Laing R, Stephens P, Ross-Degnan D. Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey methodology. *Rev Panam Salud Publica* 2010; 27 (4) doi:10.1590/S1020-49892010000400008

74. Mendis S, Fukino K, Cameron A, Laing R, Filipe Jr A, Oussama K, Leowski J, Ewen M. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. *Bulletin World Health Organ* 2007; 85(4): 279-287.
75. Musoke D, Sodemann M. Availability of essential medicines across levels of care in Gulu District, Northern Uganda. *Am J Pharm Sci* 2016;4(1):11-14 doi:10.12691/ajps-4-1-3.
76. Mhlanga BS, Suleman F. Price, availability and affordability of medicines. *Afr J Prm Health Care Fam Med* 2014; 6(1), Art. #604, 6 pages. doi:10.4102/phcfm.v6i1.604
77. Van Mourik MSM, Cameron A, Ewen M, Laing RO. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. *BMC Cardiovascular Disorders* 2010;10:25 doi:10.1186/1471-2261-10-25.
78. Volman B. Direct costs and availability of diabetes medicines in low-income and middle-income countries. Geneva: World Health Organization and Health Action International, 2008
79. Cameron A, Bansal A, Dua T, Hill SR, Moshe SL, Mantel-Teeuwisse AK, Saxena, S. Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries. *Epilepsia* 2012:1-8. doi: 10.1111/j.1528-1167.2012.03446.x
80. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HGM, Laing RO. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. *Bull World Health Organ* 89(6): 279-287.
81. United Nations MDG Gap Task Force Report. MDG Goal 8. Taking stock of the global partnership for development. New York: United Nations, 2015.
82. Intellectual Property Watch. WHO Director questions IP Rights, drug prices, industry influence. 2015. Available at <http://www.ip-watch.org/2015/11/12/who-director-questions-ip-rights-drug-prices-industry-influence/>
83. DiJulio B, Firth J, Brodie M. Kaiser Health Tracking Poll: June 2015. The Henry J. Kaiser Family Foundation. Available at: <http://kff.org/health-costs/poll-finding/kaiser-health-tracking-poll-june-2015/>
84. Drug Watch <https://www.drugwatch.com/manufacturer/>
85. WHO/HAI price database: surveys in Shaanxi Province in 2010, 2012 and 2014, Shanghai Province 2006 and Shandong Province 2004. Available at <http://haiweb.org/what-we-do/price-availability-affordability/price-availability-data/>
86. Ministry of Health. 2008b. China Health Statistical Yearbook 2008. Available at <http://61.49.18.65/publicfiles/business/htmlfiles/zwgkzt/ptjnj/year2008/4.htm>
87. Wenhui M, Wen C. The zero mark-up policy for essential medicines at primary level facilities. China case study. Geneva: World Health Organization, 2015. Available at http://www.who.int/health_financing/documents/Efficiency_health_systems_China/en/
88. Ewen M, Joesse HJ, Beran D, Laing R. Insulin prices, availability and affordability in 15 low- and middle-income countries. Health Action International, 2016 (forthcoming)
89. Kotwani A, Levison L. Price components and access to medicines in Delhi, India. Available at <http://apps.who.int/medicinedocs/documents/s19208en/s19208en.pdf>
90. Waning B, Maddix J and Soucy L. Balancing medicine prices and business sustainability: analyses of pharmacy costs, revenues and profit shed light on retail medicine mark-ups in rural Kyrgyzstan. *BMC Health Services Research* 2010; 10: 205. Available at <http://www.biomedcentral.com/1472-6963/10/205>
91. Olcay M, Laing R. Pharmaceutical tariffs: What is their effect on prices, protection of local industry and revenue generation? CIPIH study, The Commission on Intellectual Property Rights, Innovation and Public Health, World Health Organization, 2005.

92. European Commission Working Document: Developing countries' duties and taxes on essential medicines used in the treatment of the major communicable diseases. Brussels, European Commission, 2003.
93. Levison L, Laing R. The hidden costs of essential medicines. *Essential Drugs Monitor* 2003;33: 20-21. Available at <http://apps.who.int/medicinedocs/en/d/Js4941e/4.8.html#Js4941e.4.8>
94. Miller RG, Secrest AM, Sharma RK, Songer TJ, Orchard TJ. Improvements in the life expectancy of type 1 diabetes: the Pittsburg Epidemiology of Diabetes Complications study cohort. *Diabetes* 2012;61:2987-92.
95. Wirtz V. Insulin Market Profile. Amsterdam: Health Action International, 2016. Available at http://haiweb.org/wp-content/uploads/2016/04/ACCISS_Insulin-Market-Profile_FINAL.pdf
96. Dylst P, Simeons S. Does the market share of generic medicines influence the price level? A European analysis. *PharmacoEconomic*. 2011;29(10):875-82. doi: 10.2165/11585970-000000000-00000.
97. Olson LM, Wendling BW. The effect of generic drug competition on generic drug prices during the Hatch-Waxman 180-day exclusivity period. Working paper No. 317 April 2013, Bureau of Economics Federal Trade Commission, Washington DC, USA. Available at <https://www.ftc.gov/sites/default/files/documents/reports/estimating-effect-entry-generic-drug-prices-using-hatch-waxman-exclusivity/wp317.pdf>
98. Beran D. Improving access to insulin: what can be done? *Diabetes Manage* 2011;1:67-76.
99. Ewen M, Joosse HJ and Ashigbie P. Insulin Prices Profile. Amsterdam: Health Action International, 2016. Available at http://haiweb.org/wp-content/uploads/2016/04/ACCISS-Prices-report_FINAL-1.pdf
100. World Health Organization. Ten facts on essential medicines. Fact No. 1. Available at http://www.who.int/features/factfiles/essential_medicines/essential_medicines_facts/en/
101. World Health Organization. Ten facts on essential medicines. Fact No. 5. Available at http://www.who.int/features/factfiles/essential_medicines/essential_medicines_facts/en/
102. Dixit R, Vinay M, Jayasree T, Ubedulla S, Manohar VS, Chandrasekhar N. Availability of essential medicines: A primary health care perspective. *Indian J Pharmacol* 2011;43(5):599-600.
103. Gitanjali B, Manikandan S. Availability of five essential medicines for children in public health facilities in India: A snapshot survey. *J Pharmacol Pharmacother* 2011;2(2):95-99.
104. Balasubramaniam R, Beneragama B, Ranganathan SS. A national survey of availability of key essential medicines for children in Sri Lanka. *Ceylon Medical Journal*. 2011;56(3):101-107. doi: <http://doi.org/10.4038/cmj.v56i3.3597>
105. Chen W, Tang S, Sun J, Ross-Degnan D, Wagner AK. Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces. *BMC Health Serv Res* 2010;10:211.
106. UNRWA. Medicine procurement prices and processes in the United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA). Jordan: UNRWA, 2011. Available at <http://www.unrwa.org/resources/reports/medicine-procurement-prices-and-processes-unrwa>
107. Ministry of Health and Ministry of Industry, Federal Democratic Republic of Ethiopia. National strategy and plan of action for pharmaceutical manufacturing development in Ethiopia (2015-2025). Developing the pharmaceutical industry and improving access. July 2015. http://www.who.int/phi/publications/Ethiopia_strategy_local_production.pdf
108. Niëns LM, Van de Poel E, Cameron A, Ewen M, Laing R, Brouwer WBF. Practical measurement of affordability: an application to medicines. *Bulletin of the World Health Organ* 2012;90:219-227.
109. Wong J, Richelcyn J, Baclay M et al. How effective has the Generics Act been? Philippine Institute for Development Studies. Policy Notes 2016:06.
110. World Health Organization. Medicine prices, availability and affordability. The World Medicines Situation 2011. Available at <http://apps.who.int/medicinedocs/en/m/abstract/Js18065en/>

111. Cameron A, Mantel-Teeuwisse AK, Leufkens HGM, Laing RL. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? *Value in Health* 2012;15(5):664-673.
112. Ewen M. Developing and Implementing medicine pricing policies in resource-constrained pharmaceutical settings. Briefing note from regional consultations. World Health Organization, 2013 (unpublished).
113. King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. *Croatian Med J* 2002;43(4):462-469.
114. Kaplan W, Wirtz V, Nguyen A, Ewen M, Vogler S, Laing R. Policy options for promoting the use of generic medicines in low- and middle-income countries. (unpublished)
115. Kaplan WA, Ritz LS, Vitello M, Wirtz VJ. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. *Health Policy* 2012;106(3):211-24. doi: 10.1016/j.healthpol.2012.04.015
116. Lapteva M, Kalia YN. Comparison of regulatory guidelines for insulins/biosimilars. School of Pharmaceutical Sciences, University of Geneva report for the ACCISS Study. 2016 (forthcoming)
117. Personnel communications with a biosimilar manufacturer, 2016.
118. Minghetti P, Rocco P, Cilurzo F, Vecchio LD, Locatelli F. The regulatory framework of biosimilars in the European Union. *Drug Discov Today* 2012;17:63–70.
119. Gray AL. Medicine pricing interventions-the South African experience. *Southern Med Review* 2009;2(2):15-19.
120. Vogler S, Zimmermann N, Habl C, Piessneggar J, Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. *Southern Med Review* 2012;5(1):38–46.

